In addition, the current work examined the proliferative activity of AD- and the BM-MSCs using the immunofluorescence and the immunohistochemistry staining of the proliferative indicators Ki-67 and PCNA, respectively, which revealed increased expression in the group receiving AD-MSCs, which were more effective in the MT pre-treated group. This evidence concerns the gene PCNA and Alzheimer disease.